Health Condition 1: L819- Disorder of pigmentation, unspecified Health Condition 2: E858- Other amyloidosis
Conditions
Interventions
Intervention1: Fractional CO2
laser therapy: Fractional CO2
laser therapy-
SUDARFRAX (0.1W to 30W) DC excited glass tube).
3 sessions
with 4 weeks interval (monthly once for 3 months)
Control Interv
Sponsors
Dr Roshany V
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with clinical diagnosis of Primary Cutaneous macular amyloidosis. 2. Patients with age 18 years and above.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women. 2. Personal history of hypertrophic scarring, keloids, melanoma or other skin cancer. 3. Patients on anti-coagulant therapy. 4. Those who had been previously treated with any laser within 3 months and any topical hypopigmenting agents within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Percentage improvement in the degree of pigmentation 2. Percentage improvement in area of skin lesion 3. Overall improvement 4. Patient satisfactionTimepoint: Baseline, 4 weeks, 8 weeks and 20 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mean difference in the pattern of Rippling post treatment. 2. Mean difference in the itching scores post treatment.Timepoint: Baseline and 20 weeks | — |
Countries
India
Contacts
Public ContactDr Brinda G David
Sri Venkateshwaraa Medical College hospital & research centre
Outcome results
None listed